OncoMatch/Clinical Trials/NCT06473961
A Phase Ib Study of GC101 in NSCLC
Is NCT06473961 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Autologous Tumor Infiltrating Lymphocytes for non small cell lung cancer metastatic.
Treatment: Autologous Tumor Infiltrating Lymphocytes — 20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Metastatic disease required
Patients with unresectable advanced, recurrent, or metastatic non-small cell lung cancer; at least 1 measurable lesion (according to RECIST1.1 criteria)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: targeted therapy
have failed after targeted ... chemotherapy
Must have received: platinum-based chemotherapy
have failed after ... platinum-containing dual chemotherapy
Cannot have received: systemic therapy
More than 5-line system therapy had been used in previous 3 years before screening period
Cannot have received: cellular therapy
receipt of a comparable cellular therapy within 28 days prior to infusion
Lab requirements
Blood counts
WBC ≥2.5×10^9/L; ANC ≥1.5×10^9/L; ALC ≥0.7×10^9/L; Platelet ≥100×10^9/L; INR ≤1.5×ULN; APTT ≤1.5×ULN
Kidney function
Serum Creatinine ≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance ≥60mL/min; Urine protein <2+, or 24-hour urine protein <1g
Liver function
ALT/AST ≤3×ULN; Total Bilirubin ≤1.5×ULN
Cardiac function
NYHA class III or IV congestive heart failure with ejection fraction <50% excluded; severe cardiac rhythm or conduction abnormalities excluded; ECG QTcF ≥450ms excluded
With sufficient hematology and end-organ function as defined by the following laboratory test results ... see inclusion criterion 8 and exclusion criterion 7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify